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S12 Journal of Thoracic Oncology Vol. 11 No. 2Slung tumor formation in Type II cells. Finally, using an in
vitro 3D tumor sphere culture system derived from Kras
activated Type II cells, we discovered small molecules
that speciﬁcally inhibit KrasG12D driven tumor sphere
formation by differentiation of Type II cells to Kras-resis-
tant proximal cells. Our ﬁndings could provide new ther-
apeutic strategies to target Kras-activated lung cancer by
either blocking Type II cell dedifferentiation or promot-
ing Type II cell proximalization.Adenocarcinoma indolence and
progression: Biological basisCharles A. Powell Icahn School of Medicine at
Mount Sinai, New York, NYLung adenocarcinoma can progress from an indolent in
situ carcinoma to an invasive, aggressive, metastatic tu-
mor. The WHO/IASLC/ATS Lung adenocarcinoma clas-
siﬁcation emphasizes the distinction of adenocarcinoma
in situ (AIS) and minimally invasive adenocarcinoma
from their invasive counterparts. Molecular biomarkers
of invasion can distinguish invasive from non-invasive
tumors, a distinction that is typically difﬁcult to make in
small biopsies and cytology specimens and is becoming
increasingly important as the recognition of early stage
adenocarcinoma increases with the widespread imple-
mentation of lung cancer screening programs in the
United States.
The early stage in tumor progression to a state of
invasiveness and metastasis is characterized by epithe-
lial dysregulation and instability that drives loss of
cellular adhesion and increased cell mobility and pro-
liferation. In many cases, signaling pathways important
in lung development are critical for mediating these
processes. The biological processes required for this
progression include alterations in the TGF-Beta signaling
pathway, and genomic copy number alterations of CDK4
and MDM2, and mutations in key oncogenic regulators.
Equally important in mediating adenocarcinoma
progression is the contribution by the tumor micro-
environment. The microenvironment is a complex
system comprised of stromal ﬁbroblasts, macro-
phages, lymphocytes, other bone marrow-derived
cells (BMDCs), and extracellular matrix (ECM) that in
a reciprocal fashion, can contribute to tumor regres-
sion or progression. Key regulators of the tumor
microenvironment regulation of tumor progression
include the TGF-Beta signaling pathway, thrombo-
spondin-1 (Tsp-1), and the composition of the tumor
immune contexture.
Taken together, these advances in the understanding
of tumor mediated and microenvironment mediatedprocesses that regulate adenocarcinoma progression and
metastasis will drive advances in translational ap-
proaches to improve diagnosis and treatment of lung
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Small cell lung cancer (SCLC) is a neuroendocrine
subtype of lung cancer characterized by fast growth,
early dissemination, and rapid chemotherapy resis-
tance. We identiﬁed a population of long-term, tumor-
propagating cells (TPCs) in a genetically engineered
mouse model of SCLC. This population, marked by high
levels of the EpCAM and CD24 cell surface proteins, is
also prevalent in human primary SCLC tumors derived
from circulating tumor cells (CTCs). SCLC TPCs are
numerous and highly proliferative but not intrinsically
chemoresistant, indicating that not all the clinical fea-
tures of SCLC tumors can be linked to TPCs. SCLC TPCs
possess a distinct transcriptional compared to non-
TPCs, including increased neuroendocrine features and
elevated MYC activity. Importantly, genetic and phar-
macological inhibition of MYC in mouse and human
SCLC cells to non-TPC levels inhibits long-term propa-
gation but not short-term growth. These studies iden-
tify a highly tumorigenic population of SCLC cells in
mouse models, cell lines and patient CTCs. In addition,
this work provides a rationale for therapeutic strategies
aimed to reduce the activity of MYC and other possible
oncogenic drivers to eradicate SCLC TPCs, thus specif-
ically preventing the maintenance and the spread of
this aggressive disease while minimizing harmful ef-
fects on the rest of the organism.Predictive biomarkers for
immunotherapy in lung cancer:
Opportunities and challengesKurt Schalper Yale School of Medicine, New
Haven, CTThe success achieved with the use of novel immunosti-
mulatory therapies targeting the inhibitory checkpoints
February 2016 Abstracts S13CTLA-4 and PD-1 axis has changed treatment and
prognosis of diverse cancers. In addition, these de-
velopments have prompted the need to understand the
immunobiology of tumors and design the optimal cur-
rent and future therapies combining immune and non-
immune mechanisms. This progress is also accompanied
with new challenges. Possibly, two of the most critical
questions in the ﬁeld include: i) the establishment and
reﬁnement of strong predictive biomarkers and ii) the
identiﬁcation of additional non-redundant immune
inhibitory targets to treat patients with the so-called
“non-inﬂammed” tumors lacking prominent pre-existing
tumor immune inﬁltration.
Blockade of the PD-1/PD-L1 axis induces prominent
and lasting clinical responses in w20% of patients
with non-small cell lung cancer (NSCLC). Recent
studies have shown also an adequate safety proﬁle
and signiﬁcant clinical advantage of these therapies
over more traditional chemotherapy agents. The suc-
cess of these therapies uncovered the power of
blocking immune inhibitory signals that are enriched
in the tumor microenvironment. Because of the
prominent but numerically low proportion of patients
showing objective beneﬁt form PD-1 blockade, devel-
opment of predictive biomarkers is needed to reduce
overtreatment and costs associated with these com-
pounds. Diverse studies have found that expression of
PD-L1 by immunohistochemistry (IHC) and pre-exis-
tence of tumor inﬁltrating lymphocytes (TILs) are
associated with beneﬁt to these therapies, supporting
the notion that a pre-existing anti tumor immune
response is required for immune re-invigoration using
PD-1 axis blockers. However the predictive value of
IHC assays is limited and there are different PD-L1
test available that have not been standardized or
tested for equivalence. To date, only one PD-L1 IHC
assay (22C3) has been approved as companion
biomarker for PD-1 blockade in NSCLC. Recently, it
was reported that the total mutational burden or
predicted neo-antigen load detected by whole exome
sequencing analysis has the potential to inform about
the likelihood of response to the anti PD-1 compound
pembrolizumab in advanced NSCLC. However, this test
requires validation as a biomarker, standardization
and the use of sophisticated sequencing and bioin-
formatics resources that are not available in most non-
academic institutions. Inﬂammation, interferon-gamma
(IFN-g) related mRNA-based signatures and T-cell
receptor sequencing have also recently been suggested
to have association with response to PD-1 blockade.
However, their predictive value has not been demon-
strated in lung cancer and their systematic measure-
ment represents a technical challenge. Integration and
reﬁnement of available immunotherapy biomarkerscould provide optimal use of immunostimulatory
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Activating mutations in KRAS account for the most
prevalent molecularly deﬁned subset of lung adeno-
carcinoma (LUAC), yet therapeutic strategies aimed at
targeting KRAS-mutant lung tumors have achieved
limited clinical success. Breaking immune tolerance
with inhibitors of immune checkpoints, particularly
those involving the PD-1/PD-L1 axis, has emerged as a
novel paradigm in the treatment of NSCLC, leading to
the recent FDA approval of nivolumab and pem-
brolizumab. It has been postulated that KRAS-mutant
LUAC may be particularly amenable to immuno-
therapy; however, heterogeneous clinical responses
have been observed in clinical trials. We have recently
identiﬁed co-occurring genetic events as major de-
terminants of the molecular diversity of KRAS-mutant
LUAC. Speciﬁcally, KRAS-mutant lung tumors can be
segregated into three major subgroups that are
dominated, respectively, by co-occurring genetic
alterations in STK11/LKB1 (KL), TP53 (KP) and
CDKN2A/B, the latter coupled with low expression of
the TTF1 transcription factor (KC). Co-mutation
deﬁned subsets exhibit distinct biological behavior,
variable phenotypic characteristics and unique thera-
peutic vulnerabilities.
Importantly, KRAS co-mutations can also impact the
tumor immune micro-environment and may thus pro-
mote mechanisms of immune evasion that are speciﬁc to
the tumor oncogenotype. We have identiﬁed that inac-
tivation of the LKB1 serine/threonine kinase, a master
regulator or cellular bio-energetics and polarity, is
associated with a “cold” immune micro-environment
across several datasets of both chemotherapy-naïve and
platinum-refractory LUAC. This is characterized by low
densities of intra-tumoral CD3+ and CD8+ lymphocyte
sub-populations and low expression of PD-L1-positive
tumor and non-tumor cells. The mechanistic basis of this
ﬁnding as well as its implications for therapy with
